Simplifying Global Compliance
Onyx’s Drug Gets Standard Review, Accelerated Approval in Question
Washington Drug Letter
Onyx Pharmaceuticals’ multiple myeloma drug carfilzomib will receive a standard, 10-month, FDA review, another hurdle for the compound, which was expected to receive priority review.
To View This Article:
Buy This Article Now
Copyright ©2018. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing